SCHEMBL7148366

SCHEMBL7148366

O=Cc1cc(OCCCc2ccc(Cl)cc2)ccc1OCCCc1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
TUBB1 Q9H4B7 1/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
PPARG P37231 5/20 0.41
PTGES O14684 2/20 0.40
ALOX5 P09917 2/20 0.40
KCNH2 Q12809 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FFAR1 O14842 2/20 0.40
PPARD Q03181 1/20 0.40
TACR2 P21452 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
HPGD P15428 1/20 0.39
PPARA Q07869 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A4 P31645 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143354 0.90 BCHE (0.47) ALDH1A1MAOAMAOBKDM4EPPARG
SCHEMBL7148350 0.85 PTGES (0.53) MAOAMAOBPPARGPTGESALOX5
SCHEMBL7150750 0.82 TUBB1 (0.55) TUBB1MAOAMAOBL3MBTL1TACR2
SCHEMBL9075908 0.81 MEN1 (0.53) ALDH1A1KDM4EPKML3MBTL1HPGD
SCHEMBL7143453 0.81 PTGES (0.49) TUBB1MAOAMAOBPPARGPTGES
SCHEMBL21331832 0.79 ALDH1A1 (0.59) ALDH1A1MAOBPPARGKCNH2L3MBTL1
SCHEMBL7146459 0.78 PTGES (0.57) ALDH1A1MAOAMAOBPPARGPTGES
SCHEMBL12952720 0.77 PTPN1 (0.41) ALDH1A1KDM4EPKMFFAR1PPARD
SCHEMBL1790721 0.77 TUBB1 (0.50) ALDH1A1TUBB1KDM4EPPARGPTGES
SCHEMBL19342444 0.77 TUBB1 (0.47) ALDH1A1TUBB1MAOBKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA ALDH1A1 27/4885TUBB1 267/4885MAOA 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.